
June 21 (Reuters) - Eli Lilly and Co LLY.N:
LILLY'S ORAL GLP-1, ORFORGLIPRON, SHOWED COMPELLING EFFICACY AND A SAFETY PROFILE CONSISTENT WITH INJECTABLE GLP-1 MEDICINES, IN COMPLETE PHASE 3 RESULTS PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
ELI LILLY AND CO - ORFORGLIPRON LOWERS A1C BY 1.3% TO 1.6% IN PHASE 3 TRIAL
ELI LILLY AND CO - REMAINS ON TRACK TO SUBMIT ORFORGLIPRON FOR WEIGHT MANAGEMENT BY END OF YEAR